Key Takeaways

Fumarate hydratase-deficient renal cell carcinoma is a rare and aggressive kidney cancer, and treatment guidance has been unclear.

In this nonrandomized trial, the objective response rate was 56% with sintilimab combined with axitinib in this patient population.

Results also suggested that genetic alterations may predict immunotherapy responses in this disease, highlighting the importance of genetic testing.

The combination of investigational sintilimab with axitinib (Inlyta) showed promise in patients with fumarate hydratase (FH)-deficient renal cell carcinoma (RCC), according to a phase II nonrandomized trial in China.

Among 41 patients with this rare and highly aggressive RCC subtype, the objective response rate (ORR) was 56% with the combination of the PD-1 inhibitor

See Full Page